Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00606411 · ClinicalTrials.gov registry record · Early Phase 1
Efficacy and Safety of Topiramate in the Treatment of Sleep-Related Eating Disorder
A Early Phase 1 study of Sleep-Related Eating Disorder, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT00606411 is a Early Phase 1 study of Sleep-Related Eating Disorder that has completed, run by Massachusetts General Hospital. The registered enrollment target is 34 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00606411, a Early Phase 1 study of Sleep-Related Eating Disorder, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to learn about the safety and effectiveness of oral (taken by mouth) topiramate in treating Sleep-Related Eating Disorder (SRED).
Conditions Studied
Interventions
- DRUG Topiramate or Placebo
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2008-01 |
| Est. Completion | 2018-11-29 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00606411
The ClinicalTrials.gov registry entry for NCT00606411 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sleep-Related Eating Disorder appearing as the primary indexed condition, and to 1 intervention - of which Topiramate or Placebo is the first listed.
NCT00606411 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00606411 about?
NCT00606411 is a clinical study titled "Efficacy and Safety of Topiramate in the Treatment of Sleep-Related Eating Disorder". The purpose of the study is to learn about the safety and effectiveness of oral (taken by mouth) topiramate in treating Sleep-Related Eating Disorder (SRED).
What is the current status of trial NCT00606411?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 34 participants. The study started on 2008-01. Estimated completion is 2018-11-29.
What conditions does trial NCT00606411 study?
This clinical trial studies the following conditions: Sleep-Related Eating Disorder.
What interventions are being tested in trial NCT00606411?
The interventions under investigation include: Topiramate or Placebo (DRUG).
Who is sponsoring clinical trial NCT00606411?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00606411 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.